Liver cancer is the growth of abnormal cells in the liver, either starting in the liver itself or spreading there from another part of the body. It is one of the fastest-rising cancers worldwide, and outcomes depend heavily on how early it’s caught. When liver cancer is found while still confined to the liver, the five-year survival rate is about 37%. Once it has spread to distant organs, that number drops to roughly 4%.
Primary vs. Secondary Liver Cancer
There are two broad categories. Primary liver cancer starts in the liver. Secondary (or metastatic) liver cancer starts somewhere else, most commonly the breast, lung, or colon, and travels to the liver through the bloodstream. Metastatic liver cancer is actually more common than primary liver cancer, because the liver filters so much blood that cancer cells from other organs frequently end up there.
Among primary liver cancers, the most common type by far is hepatocellular carcinoma, which begins in the main liver cells. The second most common is cholangiocarcinoma, a cancer of the bile ducts inside the liver, accounting for up to 15% of primary cases. The distinction matters because these cancers behave differently and are treated with different approaches.
What Causes Liver Cancer
Most hepatocellular carcinoma develops in a liver that has already been damaged for years. The damage creates scar tissue (cirrhosis), and the constant cycle of injury and repair eventually produces cancerous cells. The leading drivers of that chronic damage are:
- Hepatitis C: Chronic hepatitis C infection is the leading cause of liver cancer in North America, Europe, and Japan. The virus spreads through blood, most often through shared needles. Before routine blood-bank screening, transfusions were another route. Over decades, hepatitis C causes cirrhosis, which sets the stage for cancer.
- Hepatitis B: Hepatitis B spreads through blood, sexual contact, and from mother to child during birth. It causes liver inflammation that can progress directly to cancer, sometimes even without cirrhosis first.
- Chronic alcohol use: Heavy drinking over many years causes cirrhosis, which increases liver cancer risk. People with hepatitis C-related cirrhosis face a higher risk than those whose cirrhosis comes from alcohol alone.
- Fatty liver disease: A buildup of fat in the liver can progress to inflammation and scarring, a condition called nonalcoholic steatohepatitis. This form of fatty liver disease is becoming a more common pathway to liver cancer as obesity rates climb. In some cases, liver cancer has developed in people with fatty liver disease who haven’t yet progressed to cirrhosis.
Cirrhosis from any cause is the single biggest risk factor. It doesn’t guarantee cancer, but it puts the liver in a state where cancerous changes are far more likely.
Symptoms to Recognize
In its early stages, liver cancer typically produces no noticeable symptoms. That’s one reason it’s so often caught late. As the tumor grows, people may begin to notice discomfort in the upper right abdomen, a hard lump just below the rib cage on the right side, or pain near the right shoulder blade or back.
Other symptoms that develop as the cancer progresses include a visibly swollen abdomen, jaundice (yellowing of the skin and the whites of the eyes), unusual tiredness, unexplained weight loss, loss of appetite, nausea and vomiting, and easy bruising or bleeding. None of these are unique to liver cancer, which is why they’re easy to dismiss or attribute to something else.
How Liver Cancer Is Diagnosed
For people at high risk, particularly those with cirrhosis or chronic hepatitis, doctors use regular screening to catch tumors before symptoms appear. The two main screening tools are ultrasound imaging of the liver and a blood test measuring alpha-fetoprotein (AFP), a protein that liver tumors often produce in elevated amounts. AFP isn’t perfectly specific, since pregnancy, hepatitis flares, and a few other cancers can also raise levels, but it remains the most widely used blood marker for liver cancer.
If screening raises a concern, the next step is usually a CT scan or MRI with contrast dye, which produces detailed cross-sectional images of the liver and can reveal a tumor’s size, location, and blood supply. In many cases, the imaging pattern alone is distinctive enough to confirm the diagnosis. When imaging is inconclusive, a liver biopsy (removing a small tissue sample with a needle) may be necessary. Biopsy carries rare but serious risks, including bleeding and the small chance of tumor cells spreading along the needle track, so it’s reserved for situations where imaging can’t provide a clear answer.
Staging and What It Means
Liver cancer staging is more complex than for most cancers because doctors have to evaluate two things at once: the tumor itself and how well the remaining liver is functioning. A small tumor in a liver that barely works is a very different situation from the same tumor in an otherwise healthy liver.
The most widely used staging framework assigns patients to one of five categories. At the earliest stage, the tumor is a single nodule no larger than 2 centimeters, and liver function is well preserved. Early-stage disease includes a single tumor or up to three small tumors, still with reasonable liver function. Intermediate-stage cancer involves multiple tumors but no spread beyond the liver. Advanced-stage cancer means the tumor has invaded blood vessels or spread outside the liver. Terminal-stage disease involves severe loss of liver function regardless of tumor size.
This staging system directly shapes treatment decisions because the best option for a patient with a small tumor and good liver function is completely different from the approach for someone whose liver is already failing.
Treatment Options
When liver cancer is caught early in a liver that still functions well, surgery to remove the tumor (resection) is one of the primary options. Resection offers the advantage of being immediately available and preserving donor organs for others. The drawback is that it doesn’t address the underlying liver disease, so recurrence rates are high, since the remaining liver tissue that gave rise to the first tumor can produce new ones.
Liver transplantation is considered the ideal treatment for eligible patients because it accomplishes two things at once: it removes the cancer and replaces the diseased liver entirely. For carefully selected candidates (generally those with a single tumor under 5 centimeters or up to three tumors each under 3 centimeters), transplant offers the best long-term disease control. The major barriers are a shortage of donor organs and the risk of the cancer progressing while waiting for a transplant.
For tumors that can’t be surgically removed, ablation therapies destroy the cancer in place using heat, cold, or chemical injection. These are most effective for small tumors. Patients with more advanced disease may receive treatments that deliver targeted radiation or chemotherapy directly to the liver’s blood supply, cutting off the tumor’s lifeline. Newer systemic therapies, including immunotherapy and targeted drugs, have expanded options for advanced-stage liver cancer in recent years, though they are generally aimed at slowing progression rather than curing the disease.
Survival Rates by Stage
Five-year relative survival rates from the most recent U.S. data paint a clear picture of why early detection matters so much. For localized liver cancer, meaning it hasn’t spread beyond the liver, the five-year survival rate is 37.4%. For regional disease that has reached nearby lymph nodes, it drops to 13.4%. For distant disease that has metastasized to other organs, the rate is 3.6%.
These numbers represent averages across all patients diagnosed in recent years. Individual outcomes vary depending on liver function, overall health, tumor biology, and whether the cancer responds to treatment. Survival rates have been slowly improving as screening becomes more widespread and new therapies enter practice, but the single most impactful factor remains catching the cancer early, which is why regular screening for people with known liver disease is so important.
Reducing Your Risk
Because most liver cancer grows out of years of liver damage, prevention centers on protecting the liver. Hepatitis B vaccination is highly effective and routinely given in infancy in most countries. Hepatitis C has no vaccine, but effective antiviral treatments can now cure the infection in most people, removing that long-term cancer risk. Limiting alcohol intake reduces the chance of cirrhosis. Maintaining a healthy weight and managing conditions like diabetes can help prevent fatty liver disease from progressing to the inflammatory stage that raises cancer risk.
For people who already have cirrhosis or chronic hepatitis, the most actionable step is consistent screening, typically an ultrasound and AFP blood test every six months. This is the window where liver cancer can still be found at a stage where curative treatment is possible.